Impax Laboratories (IPXL) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Impax Laboratories (IPXL) PT Raised to $20 at Cowen Following Strong 2Q
August 9, 2017 1:54 PM EDTCowen raised its price target on Impax Laboratories (NASDAQ: IPXL) to $20.00 (from $12.00) while maintaining a Market Perform rating.
Impax reported 2Q results that were above expectations as total revenues of $202MM were $6MM above the Street's estimate. The better revenues and better... More
